This study is for people with a type of liver cancer called hepatocellular carcinoma (HCC) that cannot be removed by surgery. The study is testing a new treatment combination: casdozokitug, toripalimab, and bevacizumab. The aim is to find out if this combination is safe and works well.

To join, participants must have advanced HCC that can't be treated with surgery or other local therapies anymore. They need at least one tumor that can be measured and has not been treated before. Participants should not have had certain treatments before or have specific types of HCC like fibrolamellar or sarcomatoid HCC. Also, those with severe fluid build-up in the abdomen or chest might not be able to join.

• The study involves taking a combination of three drugs.
• Eligibility depends on the stage and type of liver cancer.
• Some medical conditions may prevent participation.

If you have questions or think you might qualify, discuss with your doctor to see if this study is right for you.